{"id":19005,"date":"2024-01-23T11:09:21","date_gmt":"2024-01-23T10:09:21","guid":{"rendered":"https:\/\/montpellier-cancer.com\/?p=19005"},"modified":"2024-01-23T11:15:04","modified_gmt":"2024-01-23T10:15:04","slug":"embo-mol-med-2024-fgf19-and-its-analog-aldafermin-cooperate-with-myc-to-induce-aggressive-hepatocarcinogenesis","status":"publish","type":"post","link":"https:\/\/montpellier-cancer.com\/en\/embo-mol-med-2024-fgf19-and-its-analog-aldafermin-cooperate-with-myc-to-induce-aggressive-hepatocarcinogenesis\/","title":{"rendered":"EMBO mol med, 2024: FGF19 and its analog Aldafermin cooperate with MYC to induce aggressive hepatocarcinogenesis"},"content":{"rendered":"
\n

Ursic-Bedoya J., Desandr\u00e9 G., Chavey C., Marie P., Polizzi A., Rivi\u00e8re B., Guillou H., Assenat E., Hibner U., Gre\u0301goire D. <\/h2>
\n
\n

L\u2019hormone FGF19 (FGF19), dont les fonctions physiologiques incluent la r\u00e9gulation de l’hom\u00e9ostasie des acides biliaires et du glucose, est surexprim\u00e9e dans un sous-groupe agressif du carcinome h\u00e9patocellulaire (CHC). Des analogues de FGF19 ont \u00e9t\u00e9 d\u00e9velopp\u00e9s pour imiter ses effets m\u00e9taboliques h\u00e9patoprotecteurs, tout en \u00e9tant th\u00e9oriquement d\u00e9pourvus de ses effets oncog\u00e9niques. Les analogues de FGF19 sont actuellement test\u00e9s dans le cadre d\u2019essais cliniques pour des maladies m\u00e9taboliques du foie.<\/p>\n

Dans cette \u00e9tude qui a b\u00e9n\u00e9fici\u00e9 du soutien du SIRIC, l\u2019\u00e9quipe supervis\u00e9e par Damien Gr\u00e9goire (IGM Montpellier) a examin\u00e9 la coop\u00e9ration oncog\u00e9nique entre FGF19 et les voies fr\u00e9quemment mut\u00e9es dans le CHC. Utilisant un mod\u00e8le murin pr\u00e9clinique, Ursic-Bedoya, Desandr\u00e9 et al. montrent que FGF19 coop\u00e8re efficacement avec plusieurs \u00e9v\u00e9nements oncog\u00e9niques caract\u00e9ristiques du CHC, tels que l’activation de la voie Wnt\/\u03b2-catenin ou l’augmentation de l’expression de Myc. De mani\u00e8re cruciale, ils d\u00e9montrent qu\u2019un analogue de FGF19, l\u2019Aldafermin (aussi appel\u00e9 NGM282) conserve des effets oncog\u00e9niques dans ce contexte.<\/p>\n

Ces r\u00e9sultats indiquent que l’activation de la voie FGF19\/FGFR4 coop\u00e8re avec Myc pour provoquer un CHC agressif, et que l\u2019analogue Aldafermin reste oncog\u00e9nique. \u00c9tant donn\u00e9 que la voie Myc est souvent d\u00e9r\u00e9gul\u00e9e chez les patients atteints de MASH ou de cirrhose, ces travaux am\u00e8nent \u00e0 recommander la prudence quant \u00e0 l’application clinique des analogues de FGF19, en particulier dans le contexte des maladies du foie.<\/p>\n

EMBO Mol. 2024 Jan 16. doi: 10.1038\/s44321-023-00021: <\/strong>https:\/\/www.embopress.org\/doi\/epdf\/10.1038\/s44321-023-00021-x<\/a><\/p>\n

 <\/p>\n<\/div>\n <\/div>\n <\/div>\n <\/div>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":102,"featured_media":18990,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[13,39],"tags":[],"acf":[],"yoast_head":"\nEMBO mol med, 2024: FGF19 and its analog Aldafermin cooperate with MYC to induce aggressive hepatocarcinogenesis - SIRIC<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/montpellier-cancer.com\/en\/embo-mol-med-2024-fgf19-and-its-analog-aldafermin-cooperate-with-myc-to-induce-aggressive-hepatocarcinogenesis\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"EMBO mol med, 2024: FGF19 and its analog Aldafermin cooperate with MYC to induce aggressive hepatocarcinogenesis - SIRIC\" \/>\n<meta property=\"og:url\" content=\"https:\/\/montpellier-cancer.com\/en\/embo-mol-med-2024-fgf19-and-its-analog-aldafermin-cooperate-with-myc-to-induce-aggressive-hepatocarcinogenesis\/\" \/>\n<meta property=\"og:site_name\" content=\"SIRIC\" \/>\n<meta property=\"article:published_time\" content=\"2024-01-23T10:09:21+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-01-23T10:15:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/montpellier-cancer.com\/wp-content\/uploads\/OIP-1-2.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"293\" \/>\n\t<meta property=\"og:image:height\" content=\"180\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"siric.montpellier@icm.unicancer.fr\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"siric.montpellier@icm.unicancer.fr\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/montpellier-cancer.com\/en\/embo-mol-med-2024-fgf19-and-its-analog-aldafermin-cooperate-with-myc-to-induce-aggressive-hepatocarcinogenesis\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/montpellier-cancer.com\/en\/embo-mol-med-2024-fgf19-and-its-analog-aldafermin-cooperate-with-myc-to-induce-aggressive-hepatocarcinogenesis\/\"},\"author\":{\"name\":\"siric.montpellier@icm.unicancer.fr\",\"@id\":\"https:\/\/montpellier-cancer.com\/#\/schema\/person\/2994dff519d72a02fe21b5f5c9d62155\"},\"headline\":\"EMBO mol med, 2024: FGF19 and its analog Aldafermin cooperate with MYC to induce aggressive hepatocarcinogenesis\",\"datePublished\":\"2024-01-23T10:09:21+00:00\",\"dateModified\":\"2024-01-23T10:15:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/montpellier-cancer.com\/en\/embo-mol-med-2024-fgf19-and-its-analog-aldafermin-cooperate-with-myc-to-induce-aggressive-hepatocarcinogenesis\/\"},\"wordCount\":15,\"publisher\":{\"@id\":\"https:\/\/montpellier-cancer.com\/#organization\"},\"articleSection\":[\"Actualit\u00e9s professionnelles\",\"In the News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/montpellier-cancer.com\/en\/embo-mol-med-2024-fgf19-and-its-analog-aldafermin-cooperate-with-myc-to-induce-aggressive-hepatocarcinogenesis\/\",\"url\":\"https:\/\/montpellier-cancer.com\/en\/embo-mol-med-2024-fgf19-and-its-analog-aldafermin-cooperate-with-myc-to-induce-aggressive-hepatocarcinogenesis\/\",\"name\":\"EMBO mol med, 2024: FGF19 and its analog Aldafermin cooperate with MYC to induce aggressive hepatocarcinogenesis - SIRIC\",\"isPartOf\":{\"@id\":\"https:\/\/montpellier-cancer.com\/#website\"},\"datePublished\":\"2024-01-23T10:09:21+00:00\",\"dateModified\":\"2024-01-23T10:15:04+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/montpellier-cancer.com\/en\/embo-mol-med-2024-fgf19-and-its-analog-aldafermin-cooperate-with-myc-to-induce-aggressive-hepatocarcinogenesis\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/montpellier-cancer.com\/en\/embo-mol-med-2024-fgf19-and-its-analog-aldafermin-cooperate-with-myc-to-induce-aggressive-hepatocarcinogenesis\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/montpellier-cancer.com\/en\/embo-mol-med-2024-fgf19-and-its-analog-aldafermin-cooperate-with-myc-to-induce-aggressive-hepatocarcinogenesis\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/montpellier-cancer.com\/en\/home\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"In the News\",\"item\":\"https:\/\/montpellier-cancer.com\/en\/category\/business-news\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"EMBO mol med, 2024: FGF19 and its analog Aldafermin cooperate with MYC to induce aggressive hepatocarcinogenesis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/montpellier-cancer.com\/#website\",\"url\":\"https:\/\/montpellier-cancer.com\/\",\"name\":\"SIRIC\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/montpellier-cancer.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/montpellier-cancer.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/montpellier-cancer.com\/#organization\",\"name\":\"SIRIC\",\"url\":\"https:\/\/montpellier-cancer.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/montpellier-cancer.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/montpellier-cancer.com\/wp-content\/uploads\/cropped-SIRIC-montpellier-cancer-logotype-2023-FOND-TRANSPARENT.png\",\"contentUrl\":\"https:\/\/montpellier-cancer.com\/wp-content\/uploads\/cropped-SIRIC-montpellier-cancer-logotype-2023-FOND-TRANSPARENT.png\",\"width\":946,\"height\":970,\"caption\":\"SIRIC\"},\"image\":{\"@id\":\"https:\/\/montpellier-cancer.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/montpellier-cancer.com\/#\/schema\/person\/2994dff519d72a02fe21b5f5c9d62155\",\"name\":\"siric.montpellier@icm.unicancer.fr\",\"url\":\"https:\/\/montpellier-cancer.com\/en\/author\/siric-montpelliericm-unicancer-fr\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"EMBO mol med, 2024: FGF19 and its analog Aldafermin cooperate with MYC to induce aggressive hepatocarcinogenesis - SIRIC","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/montpellier-cancer.com\/en\/embo-mol-med-2024-fgf19-and-its-analog-aldafermin-cooperate-with-myc-to-induce-aggressive-hepatocarcinogenesis\/","og_locale":"en_US","og_type":"article","og_title":"EMBO mol med, 2024: FGF19 and its analog Aldafermin cooperate with MYC to induce aggressive hepatocarcinogenesis - SIRIC","og_url":"https:\/\/montpellier-cancer.com\/en\/embo-mol-med-2024-fgf19-and-its-analog-aldafermin-cooperate-with-myc-to-induce-aggressive-hepatocarcinogenesis\/","og_site_name":"SIRIC","article_published_time":"2024-01-23T10:09:21+00:00","article_modified_time":"2024-01-23T10:15:04+00:00","og_image":[{"width":293,"height":180,"url":"https:\/\/montpellier-cancer.com\/wp-content\/uploads\/OIP-1-2.jpg","type":"image\/jpeg"}],"author":"siric.montpellier@icm.unicancer.fr","twitter_misc":{"Written by":"siric.montpellier@icm.unicancer.fr","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/montpellier-cancer.com\/en\/embo-mol-med-2024-fgf19-and-its-analog-aldafermin-cooperate-with-myc-to-induce-aggressive-hepatocarcinogenesis\/#article","isPartOf":{"@id":"https:\/\/montpellier-cancer.com\/en\/embo-mol-med-2024-fgf19-and-its-analog-aldafermin-cooperate-with-myc-to-induce-aggressive-hepatocarcinogenesis\/"},"author":{"name":"siric.montpellier@icm.unicancer.fr","@id":"https:\/\/montpellier-cancer.com\/#\/schema\/person\/2994dff519d72a02fe21b5f5c9d62155"},"headline":"EMBO mol med, 2024: FGF19 and its analog Aldafermin cooperate with MYC to induce aggressive hepatocarcinogenesis","datePublished":"2024-01-23T10:09:21+00:00","dateModified":"2024-01-23T10:15:04+00:00","mainEntityOfPage":{"@id":"https:\/\/montpellier-cancer.com\/en\/embo-mol-med-2024-fgf19-and-its-analog-aldafermin-cooperate-with-myc-to-induce-aggressive-hepatocarcinogenesis\/"},"wordCount":15,"publisher":{"@id":"https:\/\/montpellier-cancer.com\/#organization"},"articleSection":["Actualit\u00e9s professionnelles","In the News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/montpellier-cancer.com\/en\/embo-mol-med-2024-fgf19-and-its-analog-aldafermin-cooperate-with-myc-to-induce-aggressive-hepatocarcinogenesis\/","url":"https:\/\/montpellier-cancer.com\/en\/embo-mol-med-2024-fgf19-and-its-analog-aldafermin-cooperate-with-myc-to-induce-aggressive-hepatocarcinogenesis\/","name":"EMBO mol med, 2024: FGF19 and its analog Aldafermin cooperate with MYC to induce aggressive hepatocarcinogenesis - SIRIC","isPartOf":{"@id":"https:\/\/montpellier-cancer.com\/#website"},"datePublished":"2024-01-23T10:09:21+00:00","dateModified":"2024-01-23T10:15:04+00:00","breadcrumb":{"@id":"https:\/\/montpellier-cancer.com\/en\/embo-mol-med-2024-fgf19-and-its-analog-aldafermin-cooperate-with-myc-to-induce-aggressive-hepatocarcinogenesis\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/montpellier-cancer.com\/en\/embo-mol-med-2024-fgf19-and-its-analog-aldafermin-cooperate-with-myc-to-induce-aggressive-hepatocarcinogenesis\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/montpellier-cancer.com\/en\/embo-mol-med-2024-fgf19-and-its-analog-aldafermin-cooperate-with-myc-to-induce-aggressive-hepatocarcinogenesis\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/montpellier-cancer.com\/en\/home\/"},{"@type":"ListItem","position":2,"name":"In the News","item":"https:\/\/montpellier-cancer.com\/en\/category\/business-news\/"},{"@type":"ListItem","position":3,"name":"EMBO mol med, 2024: FGF19 and its analog Aldafermin cooperate with MYC to induce aggressive hepatocarcinogenesis"}]},{"@type":"WebSite","@id":"https:\/\/montpellier-cancer.com\/#website","url":"https:\/\/montpellier-cancer.com\/","name":"SIRIC","description":"","publisher":{"@id":"https:\/\/montpellier-cancer.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/montpellier-cancer.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/montpellier-cancer.com\/#organization","name":"SIRIC","url":"https:\/\/montpellier-cancer.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/montpellier-cancer.com\/#\/schema\/logo\/image\/","url":"https:\/\/montpellier-cancer.com\/wp-content\/uploads\/cropped-SIRIC-montpellier-cancer-logotype-2023-FOND-TRANSPARENT.png","contentUrl":"https:\/\/montpellier-cancer.com\/wp-content\/uploads\/cropped-SIRIC-montpellier-cancer-logotype-2023-FOND-TRANSPARENT.png","width":946,"height":970,"caption":"SIRIC"},"image":{"@id":"https:\/\/montpellier-cancer.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/montpellier-cancer.com\/#\/schema\/person\/2994dff519d72a02fe21b5f5c9d62155","name":"siric.montpellier@icm.unicancer.fr","url":"https:\/\/montpellier-cancer.com\/en\/author\/siric-montpelliericm-unicancer-fr\/"}]}},"_links":{"self":[{"href":"https:\/\/montpellier-cancer.com\/en\/wp-json\/wp\/v2\/posts\/19005"}],"collection":[{"href":"https:\/\/montpellier-cancer.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/montpellier-cancer.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/montpellier-cancer.com\/en\/wp-json\/wp\/v2\/users\/102"}],"replies":[{"embeddable":true,"href":"https:\/\/montpellier-cancer.com\/en\/wp-json\/wp\/v2\/comments?post=19005"}],"version-history":[{"count":4,"href":"https:\/\/montpellier-cancer.com\/en\/wp-json\/wp\/v2\/posts\/19005\/revisions"}],"predecessor-version":[{"id":19010,"href":"https:\/\/montpellier-cancer.com\/en\/wp-json\/wp\/v2\/posts\/19005\/revisions\/19010"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/montpellier-cancer.com\/en\/wp-json\/wp\/v2\/media\/18990"}],"wp:attachment":[{"href":"https:\/\/montpellier-cancer.com\/en\/wp-json\/wp\/v2\/media?parent=19005"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/montpellier-cancer.com\/en\/wp-json\/wp\/v2\/categories?post=19005"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/montpellier-cancer.com\/en\/wp-json\/wp\/v2\/tags?post=19005"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}